• Via Ritzau pressemeddelelser
  • Via Ritzau selskabsmeddelelser
  • Globenewswire
  • Business Wire
  • ACCESSWIRE
Normal

Normal Sweden AB återkallar18.8.2022 15:37:57 CEST | Normal

Återkallelse av: POP UP BEAUTY WAX VÄRMARE EAN 5711420153379 Normal artikelnr: 10016029 Vi har konstaterat att produkten inte uppfyller kraven för elsäkerhet. Om du är i besittning av ovanstående vara måste du omedelbart sluta använda den. Apparaten säljs i NORMALs butiker i hela landet. Du kan lämna tillbaka varan till butiken och få pengarna tillbaka. Kvitto behövs inte. Normal ber naturligtvis om ursäkt för besväret. NORMAL A/S Godthåbsvej 41 DK-8660 Skanderborg
Esbjerg Kommune

Nyt projekt spørger borgerne, hvordan mennesker med demens trygt kan færdes i samfundet18.8.2022 14:33:17 CEST | Esbjerg Kommune

Hvad kan vi i fællesskab gøre, for at mennesker med demens eller andre skjulte funktionsnedsættelser i hjernen kan færdes trygt i samfundet? Det spørgsmål besvares bedst af dem, som selv oplever udfordringerne i hverdagen. Derfor inviterer Esbjerg, Varde og Fanø kommuner, Sydvestjysk Sygehus, Alzheimerforeningen og Ældre Sagen nu til borgermøder om netop dette emne.
Grünenthal Group

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain18.8.2022 13:24:23 CEST | Grünenthal Group

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi
Aquaporin A/S

Aquaporin will host webcast on August 25 to present first half 2022 results18.8.2022 12:00:00 CEST | Aquaporin A/S

Copenhagen, Denmark, August 18, 2022 – Aquaporin A/S (AQP.CO) (“Aquaporin” or the “Company”), an innovative water technology company dedicated to natural water treatment, today announced that the Company will be hosting a webcast during which the Chief Executive Officer, Matt Boczkowski, and Chief Financial Officer, Klaus Juhl Wulff, will present the results for the first half of 2022 on August 25 at 3.00 PM CET. The presentation will be followed by a Q&A session. The webcast will be conducted in English. Sign-up for the webcast via this link: https://events.q4inc.com/attendee/123834365 Dial in to ask a question: Denmark: +45 32714988 | Germany: +49 (0) 69 566 037000 | United Kingdom: + 44 (0) 203 059 58 69 | United States: +1 (0) 760 294 16 74 After the webcast, the presentation will be available via the webcast link above. For further information, please contact: Matt Boczkowski, Chief Executive Officer Klaus Juhl Wulff, Chief Financial Officer +45 53 55 55 19, investorrelations@aqua
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>